Dupilumab was proven to be an efficacious inhibitor of type II inflammation by blocking IL-4Rα, thus, it could alleviate the symptoms of AD, allergic rhinitis, and asthma at the same time (31). This evidence concerns the gene IL4R and allergic rhinitis.